Orbital and external ocular manifestations of *Mycobacterium tuberculosis*: A review of the literature

Lauren A. Dalvin, Wendy M. Smith

Department of Ophthalmology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA

**Abstract**

Tuberculosis (TB) is an airborne infectious disease caused by *Mycobacterium tuberculosis* that most commonly affects the lungs. However, extrapulmonary manifestations of TB can affect the eye and surrounding orbital tissues. TB can affect nearly any tissue in the eye, and a high index of suspicion is required for accurate diagnosis. Systemic anti-tuberculosis treatment is required in cases of ocular TB, and steroids are sometimes necessary to prevent tissue damage secondary to inflammation. Delays in diagnosis are common and can result in morbidities such as loss of an affected eye. It is important for ophthalmologists and infectious disease specialists to work together to accurately diagnose and treat ocular TB in order to prevent vision loss. This article reports the various known presentations of orbital and external ocular TB and reviews important elements of diagnosis and treatment.

**Keywords:** Tuberculosis, Mycobacterium, Orbit, Eye, Ocular

**Review of the literature**

**Background**

Tuberculosis (TB) is an infectious disease caused by the obligate aerobic, acid-fast bacillus *Mycobacterium tuberculosis* [1]. Transmission is airborne, and the lungs are the most commonly affected organ [2,3]. However, there are many forms of extrapulmonary tuberculosis, including several varieties that affect the eye [4]. This review will focus on orbital and external ocular manifestations of TB.

**Literature search strategy**

The literature was reviewed using a PubMed search with both Medical Subject Headings (MeSH) and keywords. MeSH terms included tuberculosis, ocular tuberculosis, orbital tuberculosis, eye infections and visual acuity. Keywords included eye, periocular, ocular, eyelid, conjunctiva, cornea, lacrimal gland, tuberculosis, "ocular tuberculosis," and "orbital tuberculosis." Results were limited to available peer-reviewed, English-language journals published between 1930 and 2015. All papers were reviewed, including single case reports.

**Epidemiology and pathophysiology**

According to the Centers for Disease Control and Prevention (CDC), approximately one third of the world's population is infected with TB. However, only 10% of those infected will develop clinical manifestations of the disease [5]. Of these, 16–27% have extrapulmonary manifestations, which includes those with orbital and external eye disease [6]. The precise incidence of ocular TB is much more difficult to discern, ranging from 1.4% to 18% in various studies [4,7–12]. Risk factors for extrapulmonary TB include age over 40 years, female gender, and HIV infection [4]. Hematogenous spread from the lungs is the primary mechanism by which TB affects the orbit and eyes, but TB can also spread via direct local extension [13–15]. A hypersensitivity response from infection elsewhere in the body can affect the eyes and surrounding tissues as well [13].

**External ocular involvement**

TB can affect the orbit and external eyes in a wide variety of ways, which are summarized in Table 1.

**Orbit**

TB involvement of the orbit can present as proptosis secondary to mass effect (Fig. 1) or diplopia from cranial nerve or extraocular muscle involvement [16]. Orbital involvement is usually unilateral and is more common in children, but cases have also been reported in adults [17,18]. Numerous pediatric cases of draining sinus tracts.
Fig. 1. Orbital tuberculosis presenting as proptosis. (A) Caldwell view x-ray shows bony destruction of the greater wing of the sphenoid (arrow). (B) B-scan ultrasonography reveals a retroorbital hypoechogenic area in the extraconal space (arrow). (C) Axial contrast-enhanced CT demonstrates left-sided proptosis, lacrimal abscess (arrow), and preseptal thickening (arrowhead). (D) Coronal, contrast-enhanced CT scan further illustrates destruction of the greater wing of the sphenoid (arrow) and intracranial extension (arrowhead) [18].
and radiographically-confirmed bony changes have been reported [19–21]. Involvement of the frontal, sphenoid, and zygomatic bones has been reported [17–19]. Boney involvement can be in the form of a tuberculous periostitis that typically affects the outer margin of the orbit, or it can manifest as cortical irregularities that later evolve into thickening and sclerosis of the orbital bones in longstanding cases [18,22]. Extension of orbital tuberculosis into the cranium with extradural abscess formation can occur if the condition is allowed to progress (Fig. 2) [18,23–25]. Caseating granulomas, soft tissue tuberculomas, and diffuse orbital involvement can also occur in both children and adults [20,26,27]. Finally, orbital apex syndrome has been reported, which can lead to severe vision loss [28].

Fig. 2. Orbital tuberculosis with cranial extension and extradural abscess formation. (A) Caldwell view x-ray shows loss of definition of the greater wing of the sphenoid (arrow). (B–D) Axial (B) and coronal (C, D) contrast-enhanced CT scans reveal a right-sided extraconal and lacrimal abscess (asterisk in B, C), an intracranial extradural abscess (arrowhead), and an abscess in the infratemporal fossa region (double arrowhead). (C, D) Irregularity and sclerosis of the sphenoid and zygomatic bones (arrow) is also seen [18].
Lateral such resembling eyelid granulomas also cases [29].

Fig. 3. Tuberculosis involvement of the lacrimal gland. (A) Axial contrast-enhanced CT scan shows a left lacrimal abscess (asterisk). (B, C) Coronal CT scans reveal irregularity, destruction, thickening, and sclerosis of the adjacent frontal and zygomatic bones (arrow) [18].

Table 1
Clinical presentations of external ocular tuberculosis.

| Tissue             | Possible presentations                  |
|--------------------|----------------------------------------|
| Orbit              | Periostitis                             |
|                    | Soft tissue tuberculosis                |
|                    | Bony destruction                        |
|                    | Orbital apex syndrome                   |
| Lacrimal gland     | Dacryoadenitis                          |
|                    | Abscess                                 |
| Eyelid             | Chronic blepharitis                     |
|                    | Recurrent chalazion                     |
|                    | Diffuse infiltration resembling cellulitis |
| Conjunctiva        | Conjunctivitis                          |
|                    | Subconjunctival nodules                 |
|                    | Polyps                                  |
|                    | Tuberculomas                            |
|                    | Ulcers                                  |
| Sclera             | Nodular anterior scleritis              |
|                    | Diffuse anterior scleritis              |
|                    | Scleromalacia                           |
|                    | Sclerokeratitis                         |
|                    | Sclerouveitis                           |
|                    | Posterior scleritis                     |
| Cornea             | Interstitial keratitis                  |
|                    | Disciform keratitis                     |
|                    | Phlyctenulosis                          |
|                    | Corneal erosions                        |

Lacrimal gland

The lacrimal gland can be affected in the form of dacryoadenitis [29]. The clinical presentation can be indistinguishable from bacterial dacryoadenitis, necessitating a high index of suspicion especially in cases that fail to respond to antibiotics [30]. Abscess formation can also occur (Fig. 3) [18]. Biopsy in these cases may reveal caseating granulomas [31].

Eyelid

TB in the eyelid can manifest as chronic blepharitis or nodules resembling chalazia, which recur after excision (Fig. 4) [32–36]. Four such cases have been reported in the literature. Two cases were unilateral without evidence of systemic disease, and two cases were bilateral with associated pulmonary TB [32–35]. Biopsy in such cases may reveal acid-fast bacteria, but caseating granulomas may be absent [35].

TB can also involve the eyelid secondary to extension of cutaneous involvement, which can manifest as subepithelial nodules, plaques, or ulcers [37]. Diffuse infiltration of the eyelid resembling cellulitis has also been reported with a paradoxical worsening in response to typical TB treatment, which ultimately required systemic steroids [38].

Conjunctiva

Conjunctival TB may present as conjunctivitis, subconjunctival nodules, polyps, tuberculomas, or ulcers (Figs. 5 and 6) [39–47]. While conjunctival involvement is more common in the setting of systemic disease, isolated conjunctivitis without systemic findings has been reported [48]. Phlyctenulosis can also occur as a hypersensitivity reaction that is not necessarily associated with active infection [49].

Sclera

Scleritis and scleral nodules have been reported as ocular manifestations of TB (Figs. 7 and 8) [50–53]. In fact, a previous study reported that TB was the causative agent in 10.6% of cases of infectious scleritis [31,54]. Scleritis is usually anterior, but posterior scleritis secondary to TB has been described [54,55]. Scleritis can be local or diffuse, but most cases are nodular [31,56]. Lesions can also undergo necrosis, leading to scleral thinning [31,56]. Spontaneous perforation due to necrotizing scleritis has been reported and may require excision [57]. Although scleral nodules have been hypothesized to represent an exaggerated immune response to TB elsewhere, direct infection has been proven in some cases, and pathological study has suggested that perforation occurs as a result of longstanding infection [52,53,55,57,58]. Scleritis may be associated with adjacent keratitis or uveitis [31]. TB can also affect the episclera in the form of nodular episcleritis [59].

Cornea

Patients with corneal involvement can present with pain and photophobia, with exam findings consistent with deep stromal keratitis and corneal erosions [15,60]. Patients can also develop interstitial keratitis, disciform keratitis, and phlyctenular keratoconjunctivitis due to the body’s immune response to the Mycobacterium [13,61,62].
Diagnosis

Diagnosis of ocular TB can be very difficult, as it can affect almost any part of the eye, and the clinical findings mimic those of a wide array of different underlying diseases, necessitating a complete workup to exclude other causes. Delays in diagnosis and initiation of appropriate ATT are common and may lead to significant vision loss or even loss of the eye [57]. Accurate diagnosis requires a high index of suspicion, review of associated systemic signs and symptoms, and appropriate laboratory testing. While there are no clearly defined criteria for the diagnosis of ocular TB, there are several factors that can support the diagnosis [13,63].

Clinical signs

As discussed above, TB can manifest in a wide variety of ways in the orbit and external eye. In particular, TB should be suspected in the setting of multiple recurrences despite steroids or antibiotics.

Acid-fast bacteria and histology

Acid-fast bacteria can sometimes be demonstrated via microscopy or Lowenstein-Jensen media culture of intraocular fluids or biopsied tissue, but yield is low [13,14]. A Ziehl–Neelsen stain may reveal acid-fast bacilli (Fig. 9), particularly in areas of caseous necrosis; the necrotizing granulomas themselves are also an important indication of TB [8,64].

Polymerase chain reaction

Polymerase chain reaction amplification of mycobacterial DNA can be particularly useful in ocular TB, where the sample size may be too small to detect the bacteria on microscopy or culture [47,64,65]. PCR is highly sensitive and specific and can be useful in the early diagnosis of ocular TB [14,64,66–68].

Mantoux skin test

A Mantoux skin test involves the intradermal injection of a purified protein derivative, followed by skin examination for cutaneous delayed-type hypersensitivity reaction 48–72 h after the injection (Fig. 10) [69]. The test is considered positive if the amount of induration measures greater than 5 mm in an HIV-positive patient, greater than 10 mm in high-risk persons, including healthcare workers, nursing home patients, and those living in endemic areas, and greater than 15 mm for all others [5]. In a rabbit model, cutaneous hypersensitivity has been shown to correlate directly with ocular hypersensitivity [70]. Unfortunately, this is a subjective test with low sensitivity and specificity [5]. Some patients, especially those who are immunocompromised, may have anergy to the protein and display no reaction, leading to false negative results [5]. Patients who have previously received Bacillus Calmette–Guerin (BCG) vaccinations, have been exposed to different species of mycobacteria, or who have received multiple Mantoux tests in the past, may have false positive reactions [5,13]. However, the United States Preventative Services Task Force notes that induration greater than 10 mm should not be attributed to prior BCG vaccination [71].

Interferon gamma testing

The QuantiFERON TB-Gold test (QFTG:Cellestis Ltd., Carnegie, Australia) is a blood test that detects TB and does not require a return office visit (versus the Mantoux skin test.) [72] This test specifically uses M. tuberculosis antigens to stimulate interferon gamma release from sensitized T cells in infected patients. The M. tuberculosis specific antigens used in this test will not yield false positive results for other mycobacteria or prior BCG vaccination [72,73]. Nevertheless, due to a high rate of false positive results secondary to other factors, the CDC recommends the QuantiFERON test for screening only in patients who have been vaccinated with BCG or in those who are unlikely to return for skin test reading [74]. In studies of healthcare workers screened with QuantiFERON testing, the false positive rate
was as high as 41%, and a study of HIV-positive patients revealed a false positive rate of 80.5% in those at low risk for TB [75–78].

Chest x-ray and computerized tomography

Chest x-ray or computerized tomography of the chest demonstrating cavities, consolidation, or lymph node enlargement should heighten suspicion for primary TB infection [8]. Healed or reactivated TB lesions can also be observed, and any positive chest imaging finding should prompt sputum evaluation [79]. However, it is important to keep in mind that ocular TB can occur in the absence of pulmonary TB, and the majority of chest radiographs may be normal in these patients [1,80].

Exclusion of other causes and response to treatment

It is always important to rule out other causes, such as syphilis and toxoplasmosis, when considering ocular TB [5]. Response to anti-tuberculosis treatment (ATT) may be the ultimate confirmation of ocular TB, but care should be taken not to commit patients to the required long courses of treatment without first ruling out other causes [5,81].

Treatment

Medical treatment

Patients should be managed by both an ophthalmologist and an infectious disease specialist, as systemic treatment is required to manage ocular TB. Medical ATT for ocular TB is similar to that for pulmonary TB; however, relapses of ocular TB are common and may require extended courses of treatment [57]. The CDC recommends four-drug treatment with isoniazid, rifampin, pyrazinamide, and ethambutol for a total of 2 months, followed by an additional 4–7 months of dual therapy with isoniazid and rifampin [82]. The duration of therapy may be extended due to the typically slow response in ocular TB or in cases of multi-drug resistance [13]. In cases of multi-drug resistance or patient intolerance to any of the four recommended agents, rifabutin, fluoroquinolones, interferon gamma, and linezolid can also be of use [5]. In the past, ocular TB patients with latent TB received monotherapy in the form of isoniazid and/or rifampin rather than quadruple therapy; increasingly, infectious disease specialists are recommending quadruple therapy in part to reduce the development of multidrug resistant organisms [82]. Pyridoxine (vitamin B6) supplementation should be used while patients are taking isoniazid to prevent peripheral neuropathy [83].

Ocular side effects of medical therapy

Patients should have a baseline eye exam prior to starting ATT and should be monitored for medication side effects, which can sometimes be confused with worsening ocular TB [5]. Both isoniazid and ethambutol can cause optic neuritis, commonly manifesting as decreased visual acuity, decreased color vision, and/or cecocentral scotomas [84]. Other known side effects of ethambutol include optic neuritis, red-green dyschromatopsia, disc edema, and optic atrophy [5]. The development of these side effects should prompt discontinuation of the offending medication, as the side effects can be reversible, with vision often returning to normal 10–15 weeks after drug cessation [5]. Vitamin B12 can also be used to help return vision to normal, but in some cases vision loss may be permanent [5]. Rifabutin can cause anterior uveitis that typically responds well to topical steroid treatment; very rarely, intermediate or panuveitis has been reported in association with rifabutin [1].

Conclusion

TB is one of the great mimickers; thus, ocular TB is often very difficult to diagnosis. TB can affect the orbit and external eye in a
Funding

wide variety of ways, and accurate diagnosis and treatment are crucial to preventing permanent damage. Clinicians should maintain a high index of suspicion, and ophthalmologists and infectious disease specialists should work together in the treatment of ocular TB.

Acknowledgments

Ann M. Farrell for assistance with literature search.

References

[1] Tabbaza K. Tuberculosis. Curr Opin Ophthalmol. 2007;18(6):493–501.
[2] Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. 2007 Guidelines for isolation precautions: preventing transmission of infectious agents in healthcare settings. Am J Infect Control 2007;35(Suppl. 2):S55–S164.
[3] Jones RM, Brousseau LM. Aerosol transmission of infectious disease. J Occup Environ Med 2015;57(5):501–8.
[4] Sanches L, Carvalho A, Duarte R. Who are the patients with extrapulmonary tuberculosis? Rev Port Pneumol 2014;21(2):90–3.
[5] Gupta V, Gupta A, Rao NA. Intraocular tuberculosis – an update. Surv Ophthalmol 2007;52(6):561–87.
[6] WHO. Global tuberculosis report 2012. Geneva: WHO; 2013.
[7] Yeh S, SenHN, Colyer M, Zapor M, Wroblewski K. Update on ocular tuberculosis. Curr Opin Ophthalmol 2012;23:551.
[8] Helm CJ, Holland GN. Ocular tuberculosis. Surv Ophthalmol 1993;38:229.
[9] Donahue H. Ophthalmologic experience in a tuberculosis sanatorium. Am J Ophthalmol 1967;64:742.
[10] Goldenburg M, Fabricant ND. The eye in the tuberculosis patient. Trans Sect Ophthalmol Am Med Assoc 1930;135:8.
Flocks M. Tuberculous lymphadenitis, allergic vasculitis and phlyctenulosis: report of a case. Calif Med 1953;79(4):319–22.

Sharma R, Marasini S, Nepal BP. Tubercular scleritis. Kathmandu Univ Med J. 2010;8(31):352–6.

Saini JS, Sharma A, Pillai P. Scleral tuberculosis. Trop Geog Med 1988;40(4):350–2.

Bloomfield SE, Mondino B, Gray GF. Scleral tuberculosis. Arch Ophthalmol 1976;94(6):954–6.

Nanda M, Pfiffner SC, Holland S. Mycobacterium tuberculosis scleritis. Am J Ophthalmol 1989;108(6):736.

Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Tabbara J, Sainz de la Maza MT, Foster CS. Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 cases. Ophthalmology 2012;119:1460–4.

Gupta A, Gupta V, Pandav SS, Gupta A. Posterior scleritis associated with systemic tuberculosis. Indian J Ophthalmol 2003;51:347–9.

Tabbaka K. Ocular tuberculosis: anterior section. Int Ophthalmol Clin 2005;45:57–69.

Patel SS, Saraiya NV, Tessler HH, Goldstein DA. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol 2013;131(6):752–8.

Wroblewski KJ, Hidajat AA, Neafie RC, Rao NA, Zapor M. Ocular tuberculosis: a clinicopathologic and molecular study. Ophthalmology 2011;118(4):772–7.

Bathula BP, Pappu S, Epari SR, Palaparti JB, Jose J, Ponnamalla PK. Tubercular nodular episcleritis. Indian J Chest Dis Allied Sci 2012;54:135–6.

Aclandmas WA, Kerr-Muir M. Tuberculous keratoconjunctivitis. Br J Ophthalmol 1992;76(3):175.

Kamal S, Kumar R, Kumar S, Goel R. Bilateral interstitial keratitis and granulomatous uveitis of tubercular origin. Eye Contact Lens 2014;40(2):e13–15.

Arora R, Mehta S, Gupta D, et al. Bilateral disciform keratitis at the presenting feature of extrapulmonary tuberculosis. Br J Ophthalmol 2010;94.

Ustunova E. Fundamental principles of diagnosis, differential diagnosis, and treatment of ocular tuberculosis. Visin Ophthalmol 2001;117:38–41.

Arora SK, Gupta V, Gupta A, Bambery P, Kapoor GS, Seshal S. Diagnostic efficacy of polymerase chain reaction in granulomatous uveitis. Tuberc Lung Dis 1999;70(4):229–33.

Gupta V, Arora S, Gupta A, Rao J, Bambery P, Seshal S. Management of presumed intraocular tuberculosis: possible role of the polymerase chain reaction. Acta Ophthalmol Scand 1998;76(6):679–82.

Biswas J, Madhavan HN, Gopal L, Badrinath SS. Intraocular tuberculosis. Clinico-pathologic study of five cases. Retina 1995;15:461–8.

Cassoux N, Charlotte F, Rao NA, Bodaghi B, Merle-Berar H, Lehoang P. Endoconial biopsy in establishing the diagnosis of uveitis: a clinicopathologic report of three cases. Ocul Immunol Inflamm 2005;13(1):79–83.

Van Gelder R. Applications of the polymerase chain reaction to diagnosis of ophthalmic disease. Surv Ophthalmol 2001;46:248–58.

Saka J, Matsuzawa S, Usui M, Yano I. New diagnostic approach for ocular tuberculosis by ELISA using the cord factor antigen. Br J Ophthalmol 2001;85:130–3.

Woods AC, Burky EL, Friedenwald JS. Experimental studies of ocular tuberculosis: Relation of cutaneous sensitivity to ocular sensitivity in the normal rabbit infected by injection of tubercle bacilli into the anterior chamber. Arch Ophthalmol 1938;19:245–50.

US Preventive Services Task Force. Screening for tuberculosis infection, including Bacille Calmette–Guerin immunization. Guide to clinical preventive services. US Preventive Services Task Force. 1996.

Albini TA, Karakousis PC, Rao NA. Interferon-gamma release assays in the diagnosis of tuberculous uveitis. Am J Ophthalmol 2008;146:486–8.

Kurup SK, Buggage RR, Clarke GL, Ursea R, Lim WK, Nussenblatt RB. Gamma interferon assay as an alternative to PPD skin testing in selected patients with granulomatous intraocular inflammatory disease. Con J Ophthalmol 2006;41(6):737–40.

(CDC) CIDCAP. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection. MMWR Recomm Rep 2010;59:1–25.

Gray J, Reves R, Johnson S, Belknap R. Identification of false-positive QuantiFERON-TB Gold In-Tube assays in repeat testing in HIV-infected patients at low risk for tuberculosis. Clin Infect Dis 2012;54(3):e20–3.

Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, et al. Serial testing of healthcare workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006;174:149–55.

Yoshijama T, Harada N, Higuchi K, Nakajima Y, Ogata H. Estimation of incidence of tuberculosis infection in health-care workers using repeated interferon-gamma assays. Epidemiol Infect 2009;137:1691–8.

Zwermann A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening in healthcare workers: a systematic review. Thorax 2011;66(1):62–70.

Bramante CT, Talbot EA, Rathnam SR, Stevens R, Zegans ME. Diagnosis of ocular tuberculosis: a role for new testing modalities? Int Ophthalmol 2007;27(1):45–62.

Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003;16:463–96.

Abrams J, Schlaegel TF Jr. The role of the interferon-therapy test in tuberculous uveitis. Am J Ophthalmol 1982;94:311–15.

(CDC) CIDCAP. Treatment of tuberculosis. MMWR Recomm Rep 2003;51(RR-11):1–77.

Snider D. Pyridoxine supplementation during isoniazid therapy. Tuberlc 1980;61(4):191–6.

Rodríguez-Marco NA, Solanas-Alava S, Ascaso FJ, Martínez-Martínez I, Rubio-Olano MT, Andonegui-Navarro J. Severe and reversible optic neuropathy by ethambutol and isoniazid. An Sist Sanit Navar 2014;37(2):287–91.

Alcolea A, Suarez MJ, Lizasoain M, Tejada P, Chaves F, Palenque E. Conjunctivitis with regional lymphadenopathy in a trainee microbiologist. J Clin Microbiol 2009;47(9):3043–4.

Keser MR, Edward DP, Rao NA, Sugar J, Tessler HH, Goldstein DA. Atypical infectious nodular scleritis. Arch Ophthalmol 2009;127(8):1079–80.

Kubica GP. Mycobacterium tuberculosis Ziehl–Neelsen stain 02:phil.cdc.gov CDC-PHL ID #5789. Licensed under Public Domain via Wikimedia Commons. http://commons.wikimedia.org/wiki/File:Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_5702.jpg/media/File:Mycobacterium_tuberculosis-Ziehl-Neelsen_stain_5702.jpg [accessed 07.01.15].

Mantoux test:Licensed under Public Domain via Wikimedia Commons. http://commons.wikimedia.org/wiki/File:Mantoux_test_img.jpg/media/File:Mantoux_test_img [accessed 07.01.15].

Biswas J, Aparna AC, Annamalai R, Vaijyanath K, Bagyalakshmi R. Tuberculous scleritis in a patient with rheumatoid arthritis. Ocul Immunol Inflamm 2012;20:49–52.

L.A. Dalvin, W.M. Smith / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 50–57